Implementation of Quality by Design for the Development and Validation of Pioglitazone Hydrochloride by RP-UPLC with Application to Formulated Forms

Table 9

Results of recovery study by standard addition method.

Tablet studied	PGZ 𝜇g mL^−1, tablet	PGZ 𝜇g mL^−1, pure	Total PGZ found, 𝜇g mL^−1	Percent recovery of pure PGZ; (% PGZ ± SD)
	48.58	50	99.56	100.99 ± 0.81
Oglo-15	48.58	150	196.53	98.97 ± 0.48
	48.58	250	299.13	100.18 ±0.68
	48.52	50	100.12	101.62 ± 0.85
Neoglit-30	48.52	150	195.16	98.31 ± 0.59
	48.52	250	299.60	100.36 ± 0.67